1University of Houston College of Optometry, Houston, Texas
2Ophthalmic Research Group, Aston University, Birmingham, United Kingdom
*[email protected]
Submitted: November 18, 2019
Accepted: March 5, 2020
Funding/Support: Alcon (to KR).
Conflict of Interest Disclosure: The sponsor provided financial and material support. The following authors report financial conflict of interest: A-KML, Euclid (research [R]), Novartis (R), Bausch Health (consultation [C]); KS, Euclid (R), Novartis (R); AD, Euclid (R), Novartis (R); CH, Euclid (R), Novartis (R); EST, Euclid (R), Novartis (R); MAC, Alcon (R), JJVCI (R), BLINK (R); BP, Novartis (R); JSW, Alcon (R), Allergan (R), Atia Vision (C), Contamac (C), CooperVision (C), Essilor (C), Johnson & Johnson (R), Novartis (C), Rayner (C), Théa Pharmaceuticals (C); ERR, JJVCI (R), SightGlass Vision (R), Alcon (C); and KR, Euclid (R), Novartis (R), Paragon (C), PowerVision (C). The authors were responsible for data collection, analysis, interpretation, writing this article, and the decision to submit for publication.
Study Registration Information: The study was registered on Clinical Trials.gov (registration, NCT03546647; registration date, June 5, 2018).
Author Contributions: Data Curation: A-KML, AD, KS, EST, CH, MAC, BP, MB, JSB, ERR, JSW, KR; Formal Analysis: A-KML, AD, KS, EST, CH, MAC, BP, MB, JSB, ERR, JSW, KR; Writing – Original Draft: A-KML, AD, KS, EST, CH, MAC, BP, MB, JSB, ERR, JSW, KR; Writing – Review & Editing: A-KML, AD, KS, EST, CH, MAC, BP, MB, JSB, ERR, JSW, KR.
